PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12115655-4 2002 Since the release of IL-1beta in LPS-stimulated whole blood was blocked by the caspase-1 inhibitor YVAD-cmk, processing of proIL-1beta appears to depend on caspase-1 activity. YVAD 99-103 caspase 1 Homo sapiens 79-88 14634045-7 2004 Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion. YVAD 24-28 caspase 1 Homo sapiens 4-11 14634045-7 2004 Two caspase inhibitors, YVAD (caspase 1) and DEVD (caspase 3), attenuated both BzATP-induced pore formation and IL-1beta release in a concentration-dependent fashion. YVAD 24-28 caspase 1 Homo sapiens 30-39 12115655-4 2002 Since the release of IL-1beta in LPS-stimulated whole blood was blocked by the caspase-1 inhibitor YVAD-cmk, processing of proIL-1beta appears to depend on caspase-1 activity. YVAD 99-103 caspase 1 Homo sapiens 156-165 9578463-8 1998 T7-tagged ICE, TX and TY were purified by immunoaffinity and tested for their catalytic efficiency on YVAD-containing synthetic substrates and on the ICE natural substrate, pro-interleukin-1beta. YVAD 102-106 caspase 1 Homo sapiens 10-13 9276475-8 1997 De novo caspase expression was responsible for the development of spontaneous apoptosis, since specific inhibitors of ICE (YVAD-CMK) and CPP32 (DEVD-CHO), inhibited retinoic acid induced spontaneous apoptosis. YVAD 123-127 caspase 1 Homo sapiens 118-121 9393811-8 1997 IL-1beta maturation was severely retarded by YVAD, indicating that IL-1beta-converting enzyme (ICE; caspase 1) is activated in Shigella-induced apoptosis. YVAD 45-49 caspase 1 Homo sapiens 95-98 8557034-8 1995 The specific tetrapeptide ICE inhibitor (YVAD) blocked both proteolytic activation of PKC delta and internucleosomal DNA fragmentation in IR-treated cells. YVAD 41-45 caspase 1 Homo sapiens 26-29 7499971-4 1995 Activated cells treated with YVAD-emk and ATP or CTL showed no mature IL-1 beta in either the cell lysates or the culture supernatants, indicating effective inhibition of ICE activity; however, the YVAD-treated macrophages showed no detectable change in 51Cr release or nuclear fragmentation, indicating failure to inhibit apoptotic cell death. YVAD 29-33 caspase 1 Homo sapiens 171-174 7499971-4 1995 Activated cells treated with YVAD-emk and ATP or CTL showed no mature IL-1 beta in either the cell lysates or the culture supernatants, indicating effective inhibition of ICE activity; however, the YVAD-treated macrophages showed no detectable change in 51Cr release or nuclear fragmentation, indicating failure to inhibit apoptotic cell death. YVAD 198-202 caspase 1 Homo sapiens 171-174 34935985-4 2022 In both differentiated and non-differentiated human monocytic THP-1 cells, clozapine, but not its structural analogues fluperlapine and olanzapine, caused inflammasome-dependent caspase-1 activation and IL-1beta release that was inhibited using the caspase-1 inhibitor yVAD-cmk. YVAD 269-273 caspase 1 Homo sapiens 178-187 34935985-4 2022 In both differentiated and non-differentiated human monocytic THP-1 cells, clozapine, but not its structural analogues fluperlapine and olanzapine, caused inflammasome-dependent caspase-1 activation and IL-1beta release that was inhibited using the caspase-1 inhibitor yVAD-cmk. YVAD 269-273 caspase 1 Homo sapiens 249-258 30940293-5 2019 The mortality of HCC cells was largely reversed by the caspase 1 antagonist, YVAD-cmk, suggesting that E2-induced cell death was associated with caspase 1-dependent pyroptosis. YVAD 77-81 caspase 1 Homo sapiens 55-64 35022395-10 2022 Such an effect was abrogated when THP-1 cells were incubated with YVAD (caspase-1 inhibitor) or when Caco-2 were incubated with anakinra, while butyrate incubation did not prevent such decrease. YVAD 66-70 caspase 1 Homo sapiens 72-81 32779379-9 2021 NLRP3 and Caspase-1 inhibitors (MCC950 and YVAD) significantly inhibited IL-1beta expression and NLRP3 activation, but not NLRP3 expression following exposure to BC +- pollen. YVAD 43-47 caspase 1 Homo sapiens 10-19 30940293-5 2019 The mortality of HCC cells was largely reversed by the caspase 1 antagonist, YVAD-cmk, suggesting that E2-induced cell death was associated with caspase 1-dependent pyroptosis. YVAD 77-81 caspase 1 Homo sapiens 145-154 30940293-8 2019 We observed that E2-induced pyroptosis was dramatically increased by 3-methyladenine (3-MA) treatment, which was abolished by YVAD-cmk treatment, suggesting that caspase 1-dependent pyroptosis was negatively regulated by autophagy. YVAD 126-130 caspase 1 Homo sapiens 162-171 29941706-9 2018 Ac-YVAD-cmk blocked the activation of caspase-1 and subsequently attenuated IL-1beta secretion (181.00 +- 45.24 pg/ml in LPS + MPA + YVAD group vs. 588.00 +- 41.99 pg/ml in LPS + MPA group, P = 0.014). YVAD 3-7 caspase 1 Homo sapiens 38-47 30796460-4 2019 These effects were significantly abrogated by inhibiting caspase-1 activity with inhibitor YVAD or silencing NLRP3 with siRNA in vitro, suggesting that Cd induces caspase-1- and NLRP3-inflammasome-dependent pyroptosis. YVAD 91-95 caspase 1 Homo sapiens 57-66 30944281-4 2019 We tested two inhibitors [the caspase-1 inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-cmk; hereafter referred to as YVAD), which can mitigate the LPS-induced increases in CD54 expression, and polymyxin B (PMB), which suppresses the effect of LPS by binding to its lipid moiety (i.e., the toxic component of LPS)]. YVAD 96-100 caspase 1 Homo sapiens 30-39 24495380-9 2014 Caspase-1 and Caspase-3 activities were blocked using specific inhibitors YVAD and DEVD, respectively. YVAD 74-78 caspase 1 Homo sapiens 0-9 29386662-7 2018 Moreover, caspase-1 inhibitor (YVAD) could protect breast cancer cells from DHA-induced pyroptotic cell death. YVAD 31-35 caspase 1 Homo sapiens 10-19 26168332-5 2015 Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD. YVAD 169-173 caspase 1 Homo sapiens 37-46 26168332-5 2015 Subordination of the Th1 response to caspase-1, effector of the inflammasome, was determined in explant cultures subjected to pharmacological inhibition of caspase-1 by YVAD. YVAD 169-173 caspase 1 Homo sapiens 156-165 26168332-7 2015 Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-gamma response, and a heterogenous responder group, in which both IL-18 and IFN-gamma responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD. YVAD 64-68 caspase 1 Homo sapiens 14-23 26168332-7 2015 Inhibition of caspase-1 activation using the specific inhibitor YVAD identified a homogenous non responder group featuring a caspase-1-independent IL-18/IFN-gamma response, and a heterogenous responder group, in which both IL-18 and IFN-gamma responses were caspase-1-dependent, with a 40-70% range of inhibition by YVAD. YVAD 316-320 caspase 1 Homo sapiens 14-23 25639477-6 2015 Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082. YVAD 150-154 caspase 1 Homo sapiens 130-139 24884459-6 2014 YVAD is a tetrapeptide (tyrosine-valine-alanine-aspartic acid) that specifically inhibits caspase-1, which catalyzes the production of interleukin (IL)-1beta, an inflammatory cytokine, from its inactive precursor. YVAD 0-4 caspase 1 Homo sapiens 90-99 16613759-12 2006 The cleavage product was active in the bioassay for IL-1 activity, and the caspase-1 inhibitor YVAD blocked processing. YVAD 95-99 caspase 1 Homo sapiens 75-84